Business Description
Lipigon Pharmaceuticals AB
ISIN : SE0015382072
Description
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.83 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | -1.22 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -9.2 | |||||
3-Year EBITDA Growth Rate | 33.5 | |||||
3-Year EPS without NRI Growth Rate | 32.7 | |||||
3-Year FCF Growth Rate | 31.3 | |||||
3-Year Book Growth Rate | -39.9 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.04 | |||||
9-Day RSI | 46.95 | |||||
14-Day RSI | 46.72 | |||||
6-1 Month Momentum % | -32.37 | |||||
12-1 Month Momentum % | -31.73 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 5.91 | |||||
Quick Ratio | 5.91 | |||||
Cash Ratio | 5.52 | |||||
Days Sales Outstanding | 183.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -116.1 | |||||
Shareholder Yield % | -77.09 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -78.88 | |||||
Net Margin % | -77.44 | |||||
FCF Margin % | -106.85 | |||||
ROE % | -50.74 | |||||
ROA % | -41.88 | |||||
ROIC % | -213.5 | |||||
ROC (Joel Greenblatt) % | -578.48 | |||||
ROCE % | -50.72 |
GF Value Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.78 | |||||
PB Ratio | 1.63 | |||||
Price-to-Tangible-Book | 1.61 | |||||
EV-to-EBIT | -1.32 | |||||
EV-to-EBITDA | -1.32 | |||||
EV-to-Revenue | 1.02 | |||||
EV-to-FCF | -0.83 | |||||
Price-to-Net-Current-Asset-Value | 1.61 | |||||
Price-to-Net-Cash | 1.72 | |||||
Earnings Yield (Greenblatt) % | -75.77 | |||||
FCF Yield % | -43.06 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Lipigon Pharmaceuticals AB Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil kr) | 16.407 | ||
EPS (TTM) (kr) | -0.21 | ||
Beta | 0.56 | ||
Volatility % | 63.53 | ||
14-Day RSI | 46.72 | ||
14-Day ATR (kr) | 0.037846 | ||
20-Day SMA (kr) | 0.279875 | ||
12-1 Month Momentum % | -31.73 | ||
52-Week Range (kr) | 0.2365 - 0.82 | ||
Shares Outstanding (Mil) | 148.33 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Lipigon Pharmaceuticals AB Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Lipigon Pharmaceuticals AB Stock Events
Event | Date | Price(kr) | ||
---|---|---|---|---|
No Event Data |
Lipigon Pharmaceuticals AB Frequently Asked Questions
What is Lipigon Pharmaceuticals AB(OSTO:LPGO)'s stock price today?
When is next earnings date of Lipigon Pharmaceuticals AB(OSTO:LPGO)?
Does Lipigon Pharmaceuticals AB(OSTO:LPGO) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |